NDAINHALATIONSPRAY, METERED
Approved
Oct 2011
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
3
Data completeness
5/8 — Partial
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIVENT RESPIMAT is a fixed-dose combination inhaler containing ipratropium bromide (anticholinergic) and albuterol (beta-2 agonist) delivered via metered-spray formulation. It is indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD) by combining bronchodilation through dual mechanisms. The product targets patients requiring combination therapy who benefit from both anticholinergic and short-acting beta-agonist activity.
$0.456BPart D
Peak3.9 years to LOEProduct is at peak commercial maturity with $456M in Part D spending (2023), indicating stable revenue but requiring focused retention strategies as LOE approaches in 4 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Ventilator Adapters for Combivent Respimat
Started Oct 2013
11 enrolled
Pulmonary Disease, Chronic Obstructive
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
Started Nov 2009
470 enrolled
Pulmonary Disease, Chronic Obstructive
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
Started Dec 2008
226 enrolled
Asthma
Why This Matters for Your Career
Worked on COMBIVENT RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.